Powered by a deal with Pfizer Inc., Glycomimetics Inc. is looking to solidify further its position in the race for therapies that would treat vaso-occlusive crises (VOCs) in sickle cell disease (SCD). The Gaithersburg, Md.-based company, which filed for a proposed initial public offering (IPO), but did not specify the targeted number of shares or price range, is developing GMI-1070 (rivipansel sodium) with Pfizer, of New York.